Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DPP4 | P27487 | 7/20 | 0.53 |
| ▸ | PIK3CD | O00329 | 1/20 | 0.33 |
| ▸ | HDAC4 | P56524 | 1/20 | 0.33 |
| ▸ | NAMPT | P43490 | 1/20 | 0.31 |
| ▸ | KCNQ3 | O43525 | 1/20 | 0.31 |
| ▸ | KCNQ2 | O43526 | 1/20 | 0.31 |
| ▸ | MAP4K4 | O95819 | 1/20 | 0.31 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.30 |
| ▸ | ATM | Q13315 | 1/20 | 0.30 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.30 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2746323 | 0.79 | DPP4 (0.58) | DPP4KDM4EATM | |
| SCHEMBL4122456 | 0.79 | PIK3CD (0.33) | DPP4PIK3CDHDAC4NAMPTKCNQ3 | |
| SCHEMBL1911520 | 0.75 | PIK3CD (0.43) | DPP4PIK3CDHDAC4NAMPTKDM4E | |
| SCHEMBL17152465 | 0.74 | SLC7A5 (0.42) | DPP4PIK3CDHDAC4NAMPT | |
| SCHEMBL21570251 | 0.72 | DPP4 (0.58) | DPP4 | |
| SCHEMBL21086856 | 0.72 | DPP4 (0.58) | DPP4 | |
| SCHEMBL7986296 | 0.71 | DPP4 (0.49) | DPP4 | |
| SCHEMBL7986301 | 0.71 | DPP4 (0.49) | DPP4 | |
| SCHEMBL13223495 | 0.71 | HDAC4 (0.37) | PIK3CDHDAC4NAMPTKCNQ3KCNQ2 | |
| SCHEMBL4132078 | 0.71 | DPP4 (0.47) | DPP4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8431565-B2 | Substituted imidazoheterocycles | CARA THERAPEUTICS, INC. (US) | 2013-04-30 | — | — | US | claimed |
| US-20090149450-A1 | SUBSTITUTED IMIDAZOHETEROCYCLES | CARA THERAPEUTICS, INC. (US) | 2009-06-11 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090149450-A1 | SUBSTITUTED IMIDAZOHETEROCYCLES | CNR1, CNR2, TRPV1 | DPP4 4359/4885PIK3CD 1651/4885HDAC4 1681/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.